Thursday, 18 April 2024
Trending

[the_ad_group id="2845"]

Investing

4D molecular therapeutics CLO sells $259k in stock By Investing.com

Natural Gas Inventory +95 bcf vs +88 bcf Expected By Investing.com

[the_ad id="21475"]

[ad_1]

In a recent transaction, Scott Bizily, the Chief Legal Officer (CLO) of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), sold shares totaling approximately $259,102. The transaction involved the sale of 8,153 shares of common stock at a price of $31.78 each on April 1, 2024. This sale was conducted under a pre-arranged 10b5-1 trading plan, which allows insiders of publicly traded corporations to set up a trading plan for selling stocks they own.

In addition to the sale, Bizily also engaged in multiple transactions to acquire shares through option exercises, with transaction totals for non-derivative securities amounting to $102,224. The prices for these option exercises ranged from $6.49 to $20.24, reflecting the varying strike prices of the stock options Bizily exercised.

The sale and the acquisition of shares by Bizily are part of the standard transactions that executives and insiders of companies carry out, which can be based on various personal financial strategies, including diversification, liquidity needs, or other personal investment considerations.

Following these transactions, Bizily’s ownership in 4D Molecular Therapeutics has changed, as reflected in the updated post-transaction amounts. Investors and followers of 4D Molecular Therapeutics often monitor these filings to keep track of insider activities, as they can provide insights into the executives’ perspectives on the company’s stock value and future performance.

The full details of these transactions are filed with the SEC and are publicly available for review. The company, based in Emeryville, California, operates in the biotechnology industry, focusing on the development of targeted and proprietary therapeutics.

InvestingPro Insights

As 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) navigates through its corporate and financial activities, real-time data from InvestingPro offers a glimpse into the company’s current market standing. With a Market Cap of approximately $1.39 billion USD and a striking Revenue Growth of 562.29% in the last twelve months as of Q4 2023, FDMT presents a compelling narrative for investors. Despite these impressive growth figures, the company has experienced a significant 1 Week Price Total Return of -22.16%, indicating recent volatility in its stock price.

InvestingPro Tips highlight that while FDMT holds more cash than debt, suggesting a strong balance sheet, analysts are anticipating both a sales decline and a drop in net income in the current year. The stock…

Click Here to Read the Full Original Article at All News…

[ad_2]

[the_ad id="21476"]